Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group-Reference-Cited by-同舟云学术

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Published:2015-12-29 Issue:5 Volume:30 Page:1005-1017
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Laubach J,Garderet L,Mahindra A,Gahrton G,Caers J,Sezer O,Voorhees P,Leleu X,Johnsen H E,Streetly M,Jurczyszyn A,Ludwig H,Mellqvist U-H,Chng W-J,Pilarski L,Einsele H,Hou J,Turesson I,Zamagni E,Chim C S,Mazumder A,Westin J,Lu J,Reiman T,Kristinsson S,Joshua D,Roussel M,O'Gorman P,Terpos E,McCarthy P,Dimopoulos M,Moreau P,Orlowski R Z,Miguel J S,Anderson K C,Palumbo A,Kumar S,Rajkumar V,Durie B,Richardson P G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2015356.pdf

Reference128 articles.

1. Mckenna RWKR, Kuehl WM, Grogan TM, Harris NL, Coupland RW. Plasma cell neoplasms. In: Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, 2008, pp 200–213..

2. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29–37.

3. Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075–2085.

4. Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010; 28: 4621–4629.

5. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906–917.

Cited by 198 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of a new high‐dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high‐risk myeloma: Matched‐pair comparisons with concurrent control cohorts;American Journal of Hematology;2023-12-15

2. Advanced practice nurse management in multiple myeloma treated with oral therapy;Bulletin du Cancer;2023-12

3. Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial;Clinical Cancer Research;2023-10-09

4. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study;Clinical Lymphoma Myeloma and Leukemia;2023-10

5. Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study;Leukemia & Lymphoma;2023-08-04